Prolonged Daily Temozolomide for Low-Grade Glioma

NCT00165360 · clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
46
Enrollment
OTHER
Sponsor class

Conditions

Interventions

Sponsor

Dana-Farber Cancer Institute

Collaborators